24 completed, 4 terminated, 1 suspended, 1 unknown. 14 Phase 4, 6 Phase 1, 4 Not applicable, 3 Phase 2, 2 Phase 3.
Follow Spiriva: new trials by email Literature Review of Spiriva trials Research Report on Spiriva
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparative Efficacy of Once-daily LAMA/LABA Combinations Versus Tiotropium on Constant-work-rate Cycle Endurance in COPD Tiotropium, Olodaterol, Umeclidinium - COPD (Chronic Obstructive Pulmonary Disease) | Not applicable | Suspended | Medical University of Bialystok | 100 | 2024-03-11 | 2026-10-02 |
| ANTES B+ Clinical Trial Trelegy Ellipta 100/62.5/25Mcg Inh 30D, Brimica, Duaklir - Chronic Obstructive Pulmonary Disease | Phase 4 | Terminated | Fundacio Privada Mon Clinic Barcelona | 48 | 2024-02-29 | 2025-08-14 |
| Effect of Tiotropium on Airway Remodeling in Patients With Early Stage COPD Accessed by Optical Coherence Tomography Tiotropium Inhalation Powder [Spiriva] 0.018mg, Salbutamol sulphate aerosol (Ventolin) 0.1mg - Airway Remodeling, Chronic Obstructive Pulmonary Disease | Not applicable | Completed | Guangzhou Institute of Respiratory Disease | 84 | 2019-08-01 | 2026-10-21 |
| Comparisons of Inhaled LAMA or LAMA+LABA or ICS+LABA for COPD With Bronchiectasis Symbicort, Spiriva - COPD, Bronchiectasis | Phase 4 | Unknown | Shanghai Pulmonary Hospital, Shanghai, China | 90 | 2017-09-15 | 2019-08-01 |
| PET Study to Determine Muscarinic Receptor Occupancy in Lungs After Inhalation of AZD2115 and Tiotropium AZD2115, SPIRIVA, [11C]AZ13754366 - Healthy Volunteers | Phase 1 | Completed | AstraZeneca | 19 | 2017-04-26 | 2021-08-30 |
| Comparison of the Pharmacokinetics of Tiotropium Delivered From Test Inhaler Products With Reference Tiotropium - Healthy | Phase 1 | Completed | Solventum US LLC | 38 | 2016-05-01 | 2024-12-02 |
| Duration of Long Acting Muscarinic Antagonist (LAMA) Bronchoprotection Against Methacholine Challenge Tiotropium, glycopyrronium, Respimat - Asthma | Phase 4 | Completed | University of Saskatchewan | 13 | 2015-11-01 | 2016-04-20 |
| Specific Use-result Surveillance of Spiriva Respimat in Asthmatics Spiriva - Asthma | Completed | Boehringer Ingelheim | 359 | 2015-06-01 | 2019-02-11 | |
| A Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) Subjects Arformoterol tartrate inhalation solution, Tiotropium - Chronic Obstructive Pulmonary Disease (COPD) | Phase 4 | Terminated | Sumitomo Pharma America, Inc. | 66 | 2014-11-01 | 2018-06-27 |
| Two-part Pharmacokinetic and Pharmacodynamic Study of LAS190792 in Patients With Asthma and COPD LAS190792 Dose 1, LAS190792 Dose 2, LAS190792 Dose 3 - Chronic Obstructive Pulmonary Disease (COPD), Asthma | Phase 1 | Completed | AstraZeneca | 55 | 2013-09-01 | 2019-06-21 |
| Efficacy in Walked Distance of Indacaterol vs Tiotropium in Women With COPD Secondary to Biomass (EMERALD) indacaterol, Tiotropium - COPD | Phase 4 | Completed | National Institute of Respiratory Diseases, Mexico | 40 | 2013-04-01 | 2015-10-16 |
| Efficacy and Safety of Indacaterol vs Tiotropium in Women With COPD Secondary to Biomass Exposure Indacaterol, Tiotropium - COPD | Phase 4 | Completed | National Institute of Respiratory Diseases, Mexico | 73 | 2012-09-01 | 2025-04-13 |
| Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease fluticasone furoate/vilanterol 100/25mcg, tiotropium bromide 18mcg - Pulmonary Disease, Chronic Obstructive | Phase 3 | Completed | GlaxoSmithKline | 623 | 2012-04-01 | 2017-11-09 |
| Tiotropium In Early Chronic Obstructive Pulmonary Disease Patients in China Tiotropium, placebo - Chronic Obstructive Pulmonary Disease | Phase 4 | Completed | The First Affiliated Hospital of Guangzhou Medical University | 841 | 2011-11-01 | 2016-08-11 |
| Closing Volume Interpretation and Bronchodilators Effect Indacaterol maleate, Tiotropium bromide - Healthy, COPD | Phase 4 | Completed | University of Milan | 40 | 2011-08-01 | 2014-10-29 |
| Blacks and Exacerbations on Long Acting Beta Agonists (LABA) vs. Tiotropium (BELT) Tiotropium, Salmeterol, Formoterol - Asthma | Phase 3 | Completed | Brigham and Women's Hospital | 1070 | 2011-03-30 | 2018-03-30 |
| Safety and Efficacy Study of Glyco pMDI After Single and Repeated Administration Glycopyrrolate, Tiotropium, placebo - Chronic Obstructive Pulmonary Disease (COPD) | Phase 1 / Phase 2 | Completed | Chiesi Farmaceutici S.p.A. | 65 | 2010-08-01 | 2021-10-29 |
| Tiotropium Respimat Versus HandiHaler on SaO2 and Sleep in COPD Patients tiotropium, Handihaler, Respimat - Chronic Obstructive Pulmonary Disease | Not applicable | Completed | University of Crete | 200 | 2010-03-01 | 2017-03-30 |
| The Study Will Evaluate the Effect of AZD9164 in Patients With Chronic Obstructive Pulmonary Disease AZD9164, Tiotropium, Placebo - Chronic Obstructive Pulmonary Disease | Phase 2 | Completed | AstraZeneca | 25 | 2009-06-01 | 2011-08-05 |
| Study to Evaluate the Safety and Efficacy of Inhaled PT001 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Inhaled PT001, Inhaled Placebo, Tiotropium Handihaler - Chronic Obstructive Pulmonary Disease | Phase 1 / Phase 2 | Completed | Pearl Therapeutics, Inc. | 33 | 2009-03-01 | 2013-06-21 |
Showing 20 of 31. Sign in to see all of them.
Pulmonary Disease, Chronic Obstructive (23) · Asthma (6) · Emphysema (3) · Bronchitis, Chronic (2) · Respiratory Aspiration (2) · Airway Remodeling (1) · Bronchiectasis (1) · Bronchitis (1) · Cardiovascular Diseases (1) · Lung Diseases, Obstructive (1) · Motor Activity (1) · Sleep Initiation and Maintenance Disorders (1) · Smoking (1)
Boehringer Ingelheim (4) · AstraZeneca (3) · Brigham and Women's Hospital (2) · National Institute of Respiratory Diseases, Mexico (2) · Sumitomo Pharma America, Inc. (2) · Chiesi Farmaceutici S.p.A. (1) · Fundacio Privada Mon Clinic Barcelona (1) · Gelb, Arthur F., M.D. (1) · GlaxoSmithKline (1) · Guangzhou Institute of Respiratory Disease (1) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (1) · Laval University (1) · Mayo Clinic (1) · Medical University of Bialystok (1) · Pearl Therapeutics, Inc. (1)
United States (9) · Canada (4) · China (3) · United Kingdom (3) · Italy (2) · Mexico (2) · Poland (2) · Sweden (2) · Brazil (1) · Czechia (1) · Germany (1) · Romania (1) · Spain (1)
Elliot Israel, MD (2) · Arthur F Gelb, MD (1) · Bruce D Johnson, Ph.D (1) · Colin Reisner, M.D. (1) · Darcy Marciniuk, MD (1) · Dave Singh, MD (1) · Dilini Vethanayagam, MD (1) · Don Cockcroft, MD (1) · Harissios Vliagoftis, MD (1) · Irvin Mayers, MD, FRCPC (1)
PMID 11019457, PMID 16322646, PMID 16799080, PMID 17310045, PMID 17951621, PMID 18625750, PMID 8810608, PMID 12114338, PMID 16055868, PMID 16144890, PMID 16310554, PMID 16396956, PMID 16844726, PMID 16914336, PMID 17088091, PMID 17532532, PMID 17605774, PMID 17678942, PMID 17765528, PMID 18479895, PMID 18804362, PMID 18836213, PMID 19208459, PMID 19556519, PMID 20920365, PMID 20956145, PMID 21428765, PMID 22714646, PMID 23098686, PMID 23155808, PMID 24549160, PMID 24671923, PMID 24872685, PMID 24952426, PMID 25027304, PMID 26505596, PMID 27578477, PMID 28744115, PMID 28877027, PMID 32349720, PMID 32495011, PMID 36472162, PMID 38199288, PMID 39354985, PMID 40169096
2023 (1)